Drug Patents owned by Daiichi Sankyo Inc

1. Drug name - MORPHABOND ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making Aug, 2028

(5 years from now)

US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting Aug, 2028

(5 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
60MG TABLET, EXTENDED RELEASE;ORAL Discontinued
100MG TABLET, EXTENDED RELEASE;ORAL Discontinued

2. Drug name - SAVAYSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7365205 DAIICHI SANKYO INC Diamine derivatives
Apr, 2027

(4 years from now)

CN100545160C DAIICHI SANKYO INC Diamine Derivatives
Oct, 2012

(9 years ago)

CN1894238A DAIICHI SANKYO INC Diamine Derivatives
Oct, 2012

(9 years ago)

CN1826333B DAIICHI SANKYO INC Diamine Derivatives
Mar, 2022

(6 months ago)

CN1826333A DAIICHI SANKYO INC Diamine Derivatives
Mar, 2022

(6 months ago)

EP1415992A4 DAIICHI SANKYO INC Diamine Derivatives
Aug, 2022

(a month ago)

EP1415992A1 DAIICHI SANKYO INC Diamine Derivatives
Aug, 2022

(a month ago)

EP1415992B1 DAIICHI SANKYO INC Diamine Derivatives
Aug, 2022

(a month ago)

EP1405852B9 DAIICHI SANKYO INC Diamine Derivatives
Jun, 2027

(4 years from now)

EP1405852B1 DAIICHI SANKYO INC Diamine Derivatives
Jun, 2027

(4 years from now)

EP1405852A4 DAIICHI SANKYO INC Diamine Derivatives
Jun, 2027

(4 years from now)

EP1405852A1 DAIICHI SANKYO INC Diamine Derivatives
Jun, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149532 DAIICHI SANKYO INC Pharmaceutical composition Mar, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

3. Drug name - TURALIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(5 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(5 years from now)

US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(5 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Oct, 2028

(6 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(13 years from now)

CN107531706A DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridine Ramification Of Regulated Kinase
May, 2021

(1 year, 4 months ago)

CN103497188A DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

CN101605787A DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefore
Nov, 2027

(5 years from now)

CN103497188B DAIICHI SANKYO INC Adjusting C-Fms And/Or C-Kit Active Compound And Application Thereof
Nov, 2027

(5 years from now)

CN101605787B DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

CN107548394B DAIICHI SANKYO INC A Solid Form Of The Compound For Modulating Kinase
May, 2036

(13 years from now)

CN107548394A DAIICHI SANKYO INC Solid Forms Of The Kinase Modulating Compound
May, 2036

(13 years from now)

IN271905B DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity
Nov, 2027

(5 years from now)

IN200901879P2 DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

EP2086972A2 DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

EP2086972B1 DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

EP3581573A1 DAIICHI SANKYO INC Synthesis Of A Compound That Modulates Kinases
May, 2036

(13 years from now)

EP3292122B1 DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases
May, 2036

(13 years from now)

EP3292123B1 DAIICHI SANKYO INC Solid Forms Of A Compound Modulating Kinases
May, 2036

(13 years from now)

EP3581573B1 DAIICHI SANKYO INC Synthesis Of A Compound That Modulates Kinases
May, 2036

(13 years from now)

EP3292123A1 DAIICHI SANKYO INC Solid Forms Of A Compound Modulating Kinases
May, 2036

(13 years from now)

EP3292122A1 DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases
May, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity Apr, 2028

(5 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor Jun, 2033

(10 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases May, 2036

(13 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.